Trial of HBV treatment candidate now enrolling final patient group
Virion Therapeutics has announced that it’s completed enrollment for the first two groups of adults with chronic hepatitis B virus (HBV) infection in…
Latest news & perspectives
Cour’s CNP-104 granted FDA orphan drug status for treating PBC
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to CNP-104, Cour Pharmaceuticals’ treatment candidate for primary biliary cholangitis (PBC).
Maralixibat Phase 3 trial for cholestasis-related itch is enrolling
Enrollment is ongoing in a Phase 3 clinical trial that’s designed to evaluate Mirum Pharmaceuticals’ maralixibat for treatment-resistant itching, or pruritus, associated with rare…
